Robert G. Kramer sold nearly 90,000 shares of his stock in Emergent BioSolutions, knowing that large quantities of vaccine ...

Robert Kramer was the CEO of Emergent BioSolutions, a government contractor.

An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into ...

Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence ...

Emergent BioSolutions announced the closing of a $100 million asset-backed revolving loan facility. The new credit facility is aimed at enhancing Emergent's liquidity. See how Matt Maley is ...

NYSE EBS opened at $4.74 on Wednesday. The business’s 50 day moving average price is $7.83 and its 200-day moving average price is $8.61. Emergent BioSolutions has a fifty-two week low of $1.82 and a ...

Shares of Emergent BioSolutions fell after it reached a settlement with New York Attorney General Letitia James over accusations of insider trading by the company's former chief executive. Shares fell ...

Emergent BioSolutions has faced significant challenges, with its stock price falling sharply since my previous article in July 2024. The company's updated mission focuses on combating health threats ...

Shares of Emergent Biosolutions (EBS) have been strong performers lately, with the stock up 39.7% over the past month. The stock hit a new 52-week high of $13.41 in the previous session. Emergent ...

The diversified healthcare products and services provider has another analyst tracking its fortunes. He initiated coverage of the company with a convincing buy recommendation. Emergent, which benefits ...

Emergent, which benefits from a wider-than-average range of revenue-generating activities, is now being tracked by H.C. Wainwright's Raghuram Selvaraju. He launched his coverage with a buy ...